- Conditions
- Neonatal Abstinence Syndrome
- Interventions
- Clonidine HCL
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- Up to 14 Days
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 10,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10, Spinocerebellar Ataxia Type 17, ARCA1 - Autosomal Recessive Cerebellar Ataxia Type 1
- Interventions
- CAD-1883, Placebos
- Drug
- Lead sponsor
- Cadent Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Long Beach, California • Los Angeles, California • Aurora, Colorado + 3 more
- Conditions
- Glioblastoma
- Interventions
- Positron Emission Tomography, Computed Tomography, Multiparametric Magnetic Resonance Imaging Scan, Fludeoxyglucose F-18, fluorine F 18 fluorodopa
- Procedure · Radiation
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- MELAS Syndrome
- Interventions
- Fluzone®
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Methylmalonic Acidemia, Propionic Acidemia
- Interventions
- Not listed
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 11
- States / cities
- Stanford, California • Atlanta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- educational intervention, Titrated pain management, questionnaire administration
- Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 11
- States / cities
- Hopkinsville, Kentucky • Owensboro, Kentucky • Chattanooga, Tennessee + 4 more
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Rigosertib Sodium, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Wilson Disease
- Interventions
- NCC-Sp Assay
- Diagnostic Test
- Lead sponsor
- Orphalan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Timeline
- 2023 – 2025
- U.S. locations
- 9
- States / cities
- Sacramento, California • New Haven, Connecticut • Miami, Florida + 6 more
- Conditions
- Primary Immune Deficiency Disorder
- Interventions
- octanorm 16.5%
- Biological
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 2 Years to 75 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Irvine, California • San Diego, California + 4 more
- Conditions
- Angelman Syndrome, Chromosome 15q Duplication (dup15q) Syndrome
- Interventions
- Lumbar Puncture, Blood Collection
- Procedure
- Lead sponsor
- Biogen
- Industry
- Eligibility
- Up to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- San Diego, California • Chicago, Illinois • Boston, Massachusetts + 2 more
- Conditions
- Rett Syndrome
- Interventions
- triheptanoin
- Drug
- Lead sponsor
- Center for Rare Neurological Diseases, Norcross, GA
- Other
- Eligibility
- 2 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Norcross, Georgia
- Conditions
- Phenylketonuria
- Interventions
- AG-181
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Pittsburgh, Pennsylvania • Dallas, Texas
- Conditions
- Primary Immunodeficiency
- Interventions
- Immune Globulin Intravenous, Prometic's Immune Globulin Intravenous 10%
- Biological
- Lead sponsor
- Prometic Biotherapeutics, Inc.
- Industry
- Eligibility
- 2 Years to 80 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 13
- States / cities
- Irvine, California • Los Angeles, California • Centennial, Colorado + 10 more
- Conditions
- Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- Not listed
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Miami, Florida • Chicago, Illinois + 8 more
- Conditions
- Spinocerebellar Ataxia Type 3
- Interventions
- SLS-005, Placebo
- Drug
- Lead sponsor
- Seelos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Tampa, Florida + 4 more
- Conditions
- Primary Hyperoxaluria Type 1, PH1
- Interventions
- YOLT-203, Placebo
- Genetic · Drug
- Lead sponsor
- YolTech Therapeutics Co., Ltd
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Aurora, Colorado • St Louis, Missouri + 1 more
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Andecaliximab, Placebo
- Drug
- Lead sponsor
- Ashibio Inc
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- HER2 Positive Breast Cancer, Cardiovascular Abnormalities
- Interventions
- Carvedilol
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Sickle Cell Disease
- Interventions
- Not listed
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 6 Weeks to 60 Months
- Enrollment
- 738 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 4
- States / cities
- Omaha, Nebraska • Chapel Hill, North Carolina • Cleveland, Ohio
- Conditions
- Polycystic Kidney Disease
- Interventions
- Ketogenic Diet, Ketone/Glucose Monitoring, CGM/CKM, Blood Draw, Body Composition, Change in glomerular filtration rate (mg/mmol) via magnetic resonance imaging (MRI) .
- Other · Biological
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Scoliosis, Pectus Excavatum
- Interventions
- Hypnosis
- Behavioral
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 10 Years to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Prader Willi Syndrome, Hypoglycemia
- Interventions
- Infants with Prader-Willi Syndrome
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 2 Months to 12 Months
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Severe Hemophilia A
- Interventions
- MARSTACIMAB
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 74 Years · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- La Jolla, California • Los Angeles, California • San Diego, California + 1 more
- Conditions
- Obesity Complicating Childbirth, Fetal Anomaly
- Interventions
- traxi® Panniculus Retractor
- Device
- Lead sponsor
- Prisma Health-Upstate
- Other
- Eligibility
- 16 Years and older · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Greenville, South Carolina